Nipro Corporation (8086.T) Stock
Nipro Corporation

Company profile
Nipro reported revenue of 644.59 billion JPY for fiscal year 2025, up 9.9% from fiscal year 2024, and net income of 5.11 billion JPY. That is a net profit margin of 0.8% for fiscal year 2025. Its largest business segment, Medical Related, brought in 70% of segment revenue in fiscal year 2025; Japan was the largest region with 49%. Our analysis of its filings shows revenue growing from 545.20 billion JPY in fiscal year 2023 to 644.59 billion JPY in fiscal year 2025, 8.7% a year on average. Nipro reports about 38,593 full-time employees.
What stands out
- Net income fell 54.0% in fiscal year 2025, from 11.11 billion JPY in fiscal year 2024.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Nipro Corporation
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses worldwide. The company offers renal products; interventional products, such as cardiovascular products, endovascular products, and accessories; and hospital products, including hypodermic needles, syringes, IV sets and catheters, 3-way stopcocks, infusion sets, balloon infusers, etc. It also provides cardiopulmonary products comprising oxygenators, cardioplegia heat exchangers, perfusion tubing sets, arterial filters, hemoconcentrators, and venous and arterial cannulae; and enzymes, as well as contract development and manufacturing services. In addition, the company offers pharmaceutical combination products consisting of dual chamber bags, pre-filled syringes, and half-type kits; and integrated services, such as development, manufacturing, inspection, and packaging. Further, it provides glass containers, rubber stoppers, glass tubes, and other supplies for medical use; supplies for other industries; and drug administration systems, as well as autologous bone-marrow mesenchymal stem cells, culture products, and cell preservation products. The company was founded in 1947 and is headquartered in Settsu, Japan.
Largest shareholders
- Nippon Electric Glass Co., Ltd.4.96%
- Nipro Corporation4.53%
- Asset Management One Co., Ltd.1.93%
- Nipro Employee Stock Ownership Plan1.56%
- Nomura Asset Management Co., Ltd.1.50%
Share of the company, as of September 25, 2026
Leadership
- Tsuyoshi Yamazaki — President & Representative Director, 57
- Takehito Yogo CPA — Senior MD, CFO & Director, 57
- Akihiko Yamabe — Manager of Accounting Department - Corporate Planning Division
- Kimihito Minoura — MD, Head of Value Engineering & Group DX Planning Office and Director, 53
- Toyoshi Yoshida — Senior Executive Officer, 62
How much revenue does Nipro make?
Nipro reported 644.59 billion JPY in revenue for fiscal year 2025, up 9.9% from 586.79 billion JPY in fiscal year 2024.
What is Nipro's largest business segment?
Medical Related, with 512.01 billion JPY or 70% of segment revenue in fiscal year 2025. Next: Pharmaceutical related (20%) and Pharma Packaging (9%).
Where does Nipro make most of its revenue?
Japan: 49% of revenue by region in fiscal year 2025, followed by U.S.A (20%).
What companies are similar to Nipro?
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Terumo Corporation (4543.T), Olympus Corporation (7733.T), Fukuda Denshi Co., Ltd. (6960.T), Mani, Inc. (7730.T).
Has Nipro made a profit in recent years?
Net income by fiscal year: FY2021, 14.21 billion JPY; FY2022, 13.46 billion JPY; FY2023, 4.57 billion JPY; FY2024, 11.11 billion JPY; FY2025, 5.11 billion JPY. It was profitable in each of these years.
How has Nipro's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 455.56 billion JPY; FY2022, 494.79 billion JPY; FY2023, 545.20 billion JPY; FY2024, 586.79 billion JPY; FY2025, 644.59 billion JPY.
Company Information
Data as of .
How to cite: DataPorium, “Nipro Corporation (8086.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/8086.T